Pegvisomant Reference

Plain English

What it is

Pegvisomant, sold under the brand name Somavert, is an FDA-approved prescription medicine. It treats acromegaly, a condition where the body makes too much growth hormone. It is a growth hormone receptor blocker, which means it stops growth hormone from acting on the body.

What people use it for

Doctors prescribe it for adults with acromegaly who did not get enough help from surgery or radiation, or who cannot use those treatments. It is the opposite of a growth-hormone booster. Some people online wrongly call it a GH blocker for fat loss, but that idea runs against how the drug actually works and is not supported by evidence.

What the science shows

In human studies it brought a key growth-related blood marker called IGF-1 back to normal in most people with acromegaly and eased the symptoms of too much growth hormone. This evidence is reflected in its FDA label.

The catch

This is a clinician-managed prescription medicine for a hormone disease, not a body-shaping or fat-loss tool. It needs regular liver and IGF-1 blood checks because it can raise liver enzymes. It is not a research peptide.

Reference summary

Pegvisomant has label-verified evidence in acromegaly. pepSmart surfaces label-reference content only and is not a prescribing tool.

Regulatory and posture

Categories

Hormonal

Aliases

Somavert, GH receptor antagonist

Evidence posture

human

Regulatory status

FDA-approved prescription medication (Somavert). Labeled for acromegaly in adults who have had an inadequate response to surgery and/or radiation therapy, or for whom these therapies are not appropriate. pegvisomant is a GH receptor antagonist, pharmacologically opposite to GH-axis secretagogues.

Content review status

label verified

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.